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Background
The phosphatidyl inositol 3-kinase/mammalian target of
rapamycin (PI3K/mTOR) pathway has been shown to be
involved in the development of melanoma. PI-103 is a
novel kinase inhibitor blocking PI3K class IA and
mTOR complex 1 and 2. Here, we studied the effect of
targeting the PI3K/mTORC1/mTORC2 pathway by
PI-103 and rapamycin in melanoma cells and a
melanoma mouse model.
Materials and methods
Human melanoma cell lines (518A2, 607B, A375, Mel-
Juso, SKMel-28) were treated with PI-103 and assessed
for cell viability, apoptosis and cell cycle distribution.
PI3K/mTOR protein target modulation was measured
by Western-blotting. For siRNA experiments, cells were
transfected with 50 nmol/L Silencer® Select siRNA
against PIK3CA (p110a catalytic subunit of PI3K). For
in vivo studies athymic nude mice were inoculated with
518A2 cells and treated daily with PI-103 (20 mg/kg/d)
and sirolimus (1 mg/kg/d). Paraffin-embedded xenograft
sections were stained for p-AKT (Ser473) and p-S6
(Ser240+244).
Results
Dual targeting of PI3K and mTOR by PI-103 induced
apoptosis and cell cycle arrest, and inhibited viability of
melanoma cells in vitro. Combined treatment with
PI-103 and the prototypic mTORC1 inhibitor rapamycin
led to synergistic suppression of AKT and ribosomal S6
protein phosphorylation and to induction of apoptosis.
In vivo, PI-103 and rapamycin displayed only modest
single agent activity but the combination significantly
reduced tumor growth compared to both single agents.
Conclusions
Taken together, our study underscores the importance
of the PI3K/mTORC1/mTORC2 pathway in melanoma
and demonstrates that rational combination of com-
pounds that lead to an optimal blockade of a critical
pathway (“vertical inhibition”) may provide an effective
strategy for future treatment of melanoma.
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